Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2768)	6/1/2010 12:26:04 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ANDS was up 7.59% and is still up 4.64% at present with volume of > 787Ks already > its ADV The stock is trading above the resistance at the $2.50 level bigcharts.marketwatch.com It announced last week that it has retained Lazard Freres as its strategic advisor as it pursues various avenues aimed at value recognition for its stockholders from its non-nucleoside polymerase inhibitor, ANA598, in development for the treatment of hepatitis C. <g> ANDS recently released positive safety and antiviral response data at the conclusion of 12 weeks of dosing ANA598 in combination with pegylated interferon and ribavirin in an ongoing PII. Its CEO said: "We look forward to working with Lazard as we pursue options to maximize recognition of the value inherent in the ANA598 program." ANDS plans to raise $12.5M Among its strategic alternatives are selling or licensing its hepatitis C drug, ANA598 and even the potential sale of the company.<g> As mentioned, the ACTAY is $5 It seems that with some good news it could get to the $4 level. <g> bigcharts.marketwatch.com Bernard